salarius
pharmaceuticals
report
third
quarter
financial
results
houston
globe
newswire
salarius
pharmaceuticals
nasdaq
slrx
biopharmaceutical
company
developing
treatments
pediatric
cancers
solid
tumors
cancers
announced
company
host
conference
call
live
audio
webcast
wednesday
november
et
discuss
corporate
financial
results
third
quarter
conference
call
information
interested
participants
investors
may
access
conference
call
dialing
either
international
conference
id
audio
webcast
accessible
via
investors
events
presentations
section
company
website
http
archive
webcast
remain
available
days
beginning
approximately
et
wednesday
november
salarius
pharmaceuticals
salarius
pharmaceuticals
biopharmaceutical
company
developing
cancer
therapies
patients
need
salarius
lead
candidate
seclidemstat
studied
potential
treatment
pediatric
cancers
solid
tumors
cancers
limited
treatment
options
seclidemstat
currently
phase
clinical
trial
relapsed
refractory
ewing
sarcoma
received
fast
track
designation
orphan
drug
designation
rare
pediatric
disease
designation
food
drug
administration
salarius
also
developing
seclidemstat
several
cancers
high
unmet
medical
need
second
phase
clinical
study
advanced
solid
tumors
including
prostate
breast
ovarian
cancers
salarius
received
financial
support
national
pediatric
cancer
foundation
advance
ewing
sarcoma
clinical
program
also
recipient
million
product
development
award
cancer
prevention
research
institute
texas
cprit
information
please
visit
follow
company
twitter
linkedin
contact
investor
relations
tiberend
strategic
advisors
maureen
mcenroe
cfa
miriam
miller
mmcenroe
mmiller
media
relations
tiberend
strategic
advisors
johanna
bennett
jbennett
